首页 > 市场调查报告书 > 製药

癌症骨疾病

市场调查报告书

商品编码

1357960

骨癌药物市场：依药物类型、适应症、配销通路和地区划分

Bone Cancer Drugs Market, By Drug Type ( Antimetabolites, Anthracyclines, Antibiotics, and Others ), By Disease Indication, By Distribution Channel, Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region

出版日期: 2023年09月04日 | 出版商:

Coherent Market Insights | 英文 204 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计2023年骨癌药物的全球市场规模为12.864亿美元，预计在预测期内（2023-2030年）年复合成长率为5.2%。

报告范围		报告详情
基准年	2022年	2023年市场规模	12.864 亿美元
实绩资料	2018-2021	预测期	2023-2030
预测期年复合成长率	5.20%	2030年市场规模预测	18.306 亿美元

骨癌药物全球市场占有率（%）（以药物类型），2023年

骨癌是指发生在骨骼中的各种恶性。当癌细胞扩散到骨骼时，它们会损害正常骨组织。骨癌的类型取决于首先出现该疾病的细胞和组织的类型。原发性骨恶性是在骨头本身内发生的肿瘤。许多始于身体器官或其他组织的癌症可以扩散到骨骼以及身体的其他部位。这些生长称为转移性或继发性骨恶性。大多数转移（转移）到骨骼的肿瘤起源于乳房、前列腺或肺部。在骨癌中，异常骨细胞生长失控并破坏正常骨组织。它可能从骨骼开始或扩散到身体的其他部位（称为转移）。骨癌很少见。大多数骨肿瘤是良性的，这意味着它们不会癌变或扩散到身体的其他部位。然而，它会削弱骨骼并导致骨折。良性骨肿瘤有几种常见类型：骨软骨瘤是最常见的。它在20岁以下的人群中更为常见。鉅细胞瘤见于腿部。在极少数情况下，它可能会癌变。骨样骨瘤通常发生在长骨中，通常发生在 20 岁出头的人身上。骨母细胞瘤是一种罕见的脊椎和长骨肿瘤，主要发生在年轻人身上。软骨瘤通常发生在手和脚的骨头。在许多情况下没有任何症状。这是最常见的手部肿瘤类型。因此，骨癌患病的增加预计将在预测期内推动全球骨癌治疗市场的成长。

市场动态

产品数量的增加和政府法规机构核准预计将推动预测期内全球骨癌治疗市场的成长。例如，2021年2月，美国食品药物管理局（FDA）授予骨靶向放射性药物钐-153-DOTMP（CycloSam）罕见儿科疾病认定，作为骨癌。。此核技术使用低密度钐153（可减少铕污染）和DOTMP（一种旨在防止高骨骼代谢目标部位脱靶迁移的螯合剂）。

本研究的主要特点

本报告对全球骨癌治疗市场进行了详细分析，并提出了以2022年为基准年的预测期（2023-2030）的市场规模和复合年度（年复合成长率）。
它还阐明了各个细分市场的潜在收入机会，并解释了该市场有吸引力的投资提案矩阵。
它还提供了有关市场促进因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
它根据公司亮点、产品系列、主要亮点、财务实绩和策略等参数，介绍了全球骨癌药物市场的主要企业。
该报告的见解使行销人员和公司负责人能够就未来的产品发布、类型升级、市场经营团队和行销策略做出明智的资讯。
全球骨癌药物市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
相关人员可以透过用于分析全球骨癌药物市场的各种策略矩阵来促进他们的决策。

Report Coverage	Report Details
Base Year:	2022	Market Size in 2023:	US$ 1,286.4 Mn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	5.20%	2030 Value Projection:	US$ 1,830.6 Mn

The term "bone cancer" refers to a variety of malignancies that in the bones. Normal bone tissues may suffer damage, if the cancer cells spread into a bone. The type of bone cancer depends on the cell and tissue types where the disease first manifests itself. Primary bone malignancies are tumors that originate inside the bone itself. Many cancers that start in the body organs or other tissues can spread to the bones in addition to other body parts. These growths are referred to as metastatic or secondary bone malignancies. Most tumors that metastasis (spread) to the bones are from the breast, prostate, and lung. In bone cancer, abnormal cells in bone grow out of control and destroys the normal bone tissue. It can start in bone or spread to other parts of body (called metastasis). Bone cancer is rare. Most bone tumors are benign, and thus, these are not cancerous and will not spread to other areas of your body. However, these can weaken bones and lead to fractures or other problems. There are a few common types of benign bone tumors: Osteochondroma is the most common. It is common in people under the age of 20. A giant cell tumor is present in leg. In rare cases, these can also be cancerous. Osteoid osteomas often occur in long bones, usually in the early 20s. Osteoblastoma is a rare tumor that grows in the spine and long bones, and occurs primarily in young adults. Enchondromas usually appear in the bones of hands and feet. Often there are no symptoms. It is the most common type of hand tumor. Thus, increasing prevalence of bone cancer is expected to drive growth of the global bone cancer drugs market over the forecast period.

Market Dynamics

Increasing products and approvals by government regulatory bodies is expected to drive growth of the global bone cancer drugs market over the forecast period. For instance, in February 2021, the U.S. Food and Drug Administration (FDA) granted rare pediatric disease designation to the bone-targeting radiopharmaceutical samarium-153-DOTMP (CycloSam) for use as a potential therapeutic option for patients with osteosarcoma. The nuclear technology uses low specific activity samarium-153 thatreduces europium contamination, and DOTMP, a chelator designed to prevent off-target migration and at target sites with high bone turnover.

Key features of the study:

This report provides an in-depth analysis of the global bone cancer drugs market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global bone cancer drugs market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Advaxis, Inc., Cellectar Biosciences, Inc., OPKO Health, Inc., Pfizer Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, Debiopharm Group, Merck & Co., Bayer AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical, F. Hoffmann-La Roche Ltd and Teva Pharmaceutical
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global bone cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bone cancer drugs market

Detailed Segmentation:

Global Bone Cancer Drugs Market, By Drug Type:
- Antimetabolites
- Anthracyclines
- Antibiotics
- Others (RANK ligand inhibitors, etc.)
Global Bone Cancer Drugs Market, By Disease Indication:
- Multiple Myeloma
- Osteosarcoma
- Chondrosarcoma
- Ewing's Sarcoma
Global Bone Cancer Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Bone Cancer Drugs Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- Advaxis, Inc.
- Cellectar Biosciences, Inc.
- OPKO Health, Inc.
- Pfizer Inc.
- Amgen Inc.
- Novartis AG
- Eli Lilly and Company
- Debiopharm Group
- Merck & Co
- Bayer AG
- Bristol-Myers Squibb Company
- Takeda Pharmaceutical
- F. Hoffmann-La Roche Ltd
- Teva Pharmaceutical

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Drivers
Restraints
Opportunities
Market Trends
Regulatory Scenario
New Product Launches/Approvals
Merger, Acquisition and Collaboration Scenario
PEST Analysis
PORTER's Analysis

4. Global Bone Cancer Drugs Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Bone Cancer Drugs Market, By Drug Type, 2023- 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2023-2030
- Segment Trends
Antimetabolites
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023 - 2030, (US$ Mn)
Anthracyclines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023 - 2030, (US$ Mn)
Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023 - 2030, (US$ Mn)
Others (RANK ligand inhibitors, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023- 2030, (US$ Mn)

6. Global Bone Cancer Drugs Market, By Disease Indication, 2023 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Multiple Myeloma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023- 2030, (US$ Mn)
Osteosarcoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023- 2030, (US$ Mn)
Chondrosarcoma
- Introduction
Ewing's Sarcoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

7. Global Bone Cancer Drugs Market, By Distribution Channel, 2023 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2023-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023 - 2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023 - 2030, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023- 2030, (US$ Mn)

8. Global Bone Cancer Drugs Market, By Region, 2023 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Region, 2023-2030
- Segment Trends
North America
- Market Size and Forecast,and Y-o-Y Growth, By Drug Type, 2023 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
- U.S.
- Canada
Europe
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
Asia Pacific
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Middle East
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
Africa
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2023-2030, (US$ Mn)
- North Africa
- Central Africa
- South Africa

9. Competitive Landscape

Company Profiles
- Advaxis, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Cellectar Biosciences, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- OPKO Health, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Pfizer Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Amgen Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Novartis AG
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Eli Lilly and Company
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Debiopharm Group
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Merck & Co
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Bayer AG
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Bristol-Myers Squibb Company
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Takeda Pharmaceutical
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- F. Hoffmann-La Roche Ltd.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Teva Pharmaceutical
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Analyst Views

10. Section

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

骨癌药物市场：依药物类型、适应症、配销通路和地区划分

Bone Cancer Drugs Market, By Drug Type ( Antimetabolites, Anthracyclines, Antibiotics, and Others ), By Disease Indication, By Distribution Channel, Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region

市场动态

本研究的主要特点

目录

第1章调查目的和假设

第2章市场展望

第3章市场动态、法规及趋势分析

第4章全球骨癌治疗药物市场－新型冠状病毒感染疾病（COVID-19）影响分析

第5章全球骨癌药物市场，依药物类型，2023-2030

第6章2023-2030年全球骨癌药物市场（依疾病适应症）

第7章全球骨癌药物市场，依配销通路划分，2023-2030 年

第8章2023-2030年全球骨癌药物市场（按地区）

第9章竞争形势

第10章章